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Abstract
The phenotypic diversity of breast cancer has been proposed to
result from different target cell types undergoing oncogenic
transformation and giving rise to cancer stem cells. Global gene
expression profiling revealed distinct molecular phenotypes and
some of these signatures were held to reflect the cell of origin, with
the basal carcinomas arising from basal/progenitor cells. Recent
work challenges this view by providing evidence that luminal
precursor cells are involved in the pathogenesis of basal breast
cancers and has made new links between normal cell populations
and molecular tumor phenotypes.
With 18 different histopathological entities [1], breast cancer
is a particularly complex disease. Global expression profiling
of large sets of tumors identified six molecular subtypes; the
luminal A and luminal B subtypes (both estrogen receptor
alpha-positive), the normal-like, HER2-positive, and basal
subtypes (comprising triple-negative cancers) [2], and the
claudin-low subtype [3]. Complexity may also exist within a
tumor, called tumor heterogeneity [4], where different cell
types with varying proliferation capacity, morphology, and
protein expression can coexist.
The cancer stem cell theory provides an explanation for tumor
heterogeneity. The theory proposes that a subpopulation of
tumor cells behaves like normal adult stem cells and the cells
self-renew, give rise to different cell types, and account for
resistance to therapy [5]. The cell of origin concept –
according to which the target cell sustaining the tumorigenic
hits becomes a major determinant of the tumor characteristics
due to its unique cell context – complements the cancer stem
cell theory in explaining tumor phenotypic diversity [6].
Inherent to both concepts is a model of breast epithelial cell
hierarchy with a stem/bipotential progenitor at the apex,
which gives rise to luminal or myoepithelial/basal progenitors
that in turn produce differentiated luminal or myoepithelial
cells [7].
Over the past years, evidence has accumulated that supports
the existence of cancer stem cells in solid human tumors,
including breast cancer [5,8]. Data backing the cell of origin
hypothesis, however, have not been forthcoming.
Lim and colleagues have now applied the fluorescence-
activated cell sorting approaches – which they and others
used so successfully to characterize stem cells and pro-
genitor cells in the mouse mammary gland – in conjunction
with different stem cell assays, to the human breast [9]. After
depleting dissociated breast cells for endothelial and hemato-
poetic cells, they distinguished three epithelial cell popula-
tions based on differential expression of the surface markers
CD49f (integrin alpha 6) and EpCAM (also epithelial-specific
antigen). A fourth, double-negative population – dubbed
stromal – lacked epithelial markers and expressed PDGFRβ
(CD140b).
Among the epithelial cell populations, only the
CD49fhighEpCAM– population contained cells able to give
rise to ducto-lobular structures in the humanized fat pad [8];
this population was named MaSC-enriched, in analogy to the
mouse model. In matrigel-based colony-forming assays, cells
from the MaSC-enriched population formed heterogeneous
colonies, with myoepithelial/basal cells predominating. The
CD49f+EpCAM+ population was defined as luminal
progenitors based on the ability to form luminal colonies in
this assay. The third population, CD49f–EpCAM+, did not
form colonies but expressed luminal genes such as estrogen
receptor alpha, progesterone receptor, and cytokeratin 8/18 –
and was hence considered mature luminal.
To assess how these distinct populations relate to molecular
tumor subtypes, Lim and colleagues took a dual approach.
First they used prophylactic mastectomy samples from
BRCA1 mutation carriers who develop basal carcinomas at a
higher frequency [10] and normal reduction mammoplasties
to compare the distribution of the epithelial subpopulations.
Strikingly, breast epithelium of BRCA1 mutation carriers was
enriched in luminal progenitors and was depleted for the
MaSC-enriched population. Furthermore, these luminal
progenitors were abnormal and grew independent of an
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essential growth supplement; the mature luminal population
showed slightly altered expression of progesterone receptor
and cytokeratin 5/6.
This elegant genetic approach was complemented by the
characterization of the global expression signatures for each
cell population, which were compared with the profiles of the
six tumor subtypes. The mature luminal signature was asso-
ciated with the luminal A and luminal B subtypes, whereas
the MaSC signature shared properties with the claudin-low
and normal-like subtypes. Consistent with luminal progenitors
giving rise to basal tumors, the luminal progenitor signature
resembled the basal signature.
Just as dust was beginning to settle on the notion that basal
tumors originate from stem/bipotential progenitor cells, this
work put luminal progenitors in their place. In addition, the
research provides a thought-provoking mapping of molecular
tumor subtypes to distinct cell populations identified by
fluorescence-activated cell sorting.
Yet an alternative to the cell of origin hypothesis cannot be
excluded; it is conceivable that the tumorigenic event hits
cells at any position in the hierarchy and causes acquisition of
luminal progenitor characteristics. This idea is supported for
BRCA1-associated tumors by mouse models in which
BRCA1 was ablated in different mammary cell types yet the
resulting tumors were similar [11,12].
The powerful fluorescence-activated cell sorting approaches
hold great promise to further our understanding of human
breast biology and carcinogenesis. The major challenges in
applying these techniques to highly variable human
specimens consist of standardizing every step in the
procedure and improving the current stem cell assays with
considerable limitations. As an example, a previous report
using EpCAM-CD10 sorted populations, mammospheres
and induced differentiation assays proposed mammary
stem/progenitor cells as the origin of BRCA1-associated
tumors, and also reported an increased number of cells
positive for the stem cell marker ALDH1 in the breast
epithelium of BRCA1 mutation carriers [13] – whereas Lim
and colleagues found ALDH1 expression mostly in the
stromal population [9].
With further refinements we may soon distinguish more cell
types in the human breast and be able to relate changes in
cell populations to different hormonal milieus, reproductive
stages, genetic changes, and cancer risk.
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